Synucure Therapeutics

About Synucure Therapeutics

Synucure Therapeutics Inc. is a Canadian biotechnology company founded in 2021, focused on research in brain degenerative disorders. The company aims to advance the pre-clinical work of Dr. Francesca Cicchetti on a repurposed drug, Cysteamine, which shows potential in preventing or reversing features of Parkinson's disease.

Products & Services

Cysteamine as Disease Modifying Therapy (DMT):A repurposed drug demonstrating potential to prevent or reverse features of Parkinson's disease in animal and cell models.

Patented Blood Biomarkers:Research focused on developing diagnostic tools for precise detection of Parkinson's disease through a simple blood test.

Specialties

Brain Degenerative Disorders Parkinson's Disease Research Disease Modifying Therapies Blood Biomarkers for Diagnostics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Investment T: - FT: Equity Investment	A: 2800000 MR: - FA: $2.8 million FAN: 2800000	D: 2025-04-07 FD: 2025-04-07	2 investors

Equity Investment Latest

2025-04-07

$2.8M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sylvain Chrétien

President, Chief Executive Officer and Co-Founder

D

Dr. Francesca Cicchetti

Chief Scientific Officer and Co-Founder

D

Dolorès Carballo

Senior Project Manager

D

Dr. Ben Cadieux

Key Senior Advisor

J

Jo Van Betsbrugge

Drug Development Consultant/Expert

J

Jean-Pierre Moreau

Preclinical Development Consultant/Expert

View 7 more team members with Pro

Unlock Full Team Directory

Recent News